Kodiak Sciences Inc
K27
Company Profile
Business description
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
Contact
1200 Page Mill Road
Palo AltoCA94304
USAT: +1 650 281-0850
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
113
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,765.20 | 74.30 | 0.85% |
| CAC 40 | 7,763.84 | 26.64 | 0.34% |
| DAX 40 | 24,091.62 | 160.95 | 0.67% |
| Dow JONES (US) | 42,519.64 | 214.16 | 0.51% |
| FTSE 100 | 8,787.02 | 12.76 | 0.15% |
| HKSE | 23,682.34 | 169.85 | 0.72% |
| NASDAQ | 19,398.96 | 156.34 | 0.81% |
| Nikkei 225 | 37,813.92 | 367.11 | 0.98% |
| NZX 50 Index | 12,447.37 | 120.14 | 0.97% |
| S&P 500 | 5,970.37 | 34.43 | 0.58% |
| S&P/ASX 200 | 8,539.10 | 72.40 | 0.86% |
| SSE Composite Index | 3,376.53 | 14.56 | 0.43% |